文献速递前列腺癌

按疾病体积与转移时机比较转移性激素敏感性前列腺癌的生存:一项动态网状Meta分析

Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis.
PubMed 文献 · Eur Urol · 2025-11-04

结果显示同步高瘤负荷患者从ARPI+多西他赛+ADT三联治疗中显著获益,其他亚组中ARPI+ADT双联治疗优于单用ADT。

要点

  • 同步高瘤负荷且适合多西他赛者首选三联治疗
  • 其他亚组患者ARPI+ADT双联优于单用ADT
  • 有多西他赛双联治疗无额外获益

核心结论

  • 同步高瘤负荷mHSPC且适合多西他赛的患者首选三联系统治疗
  • 其他所有亚组患者ARPI+ADT双联治疗优于单用ADT
  • 在可获得ARPI且能耐受的患者中多西他赛双联无角色

研究设计与样本

  • 动态网状Meta分析,采用LIvE合成框架,纳入评估ARPI、多西他赛或两者联合强化治疗的III期随机对照试验
  • 按预设亚组分析OS纳入9项临床试验、8990例患者、8种独特治疗

主要发现

  • 同步高瘤负荷亚组(N=5171;57%)中,ARPI+D+ADT较D+ADT显著改善OS(HR 0.72;95%CI 0.62-0.83),较ARPI+ADT亦显著改善(HR 0.71;95%CI 0.53-0.97)
  • 同步低瘤负荷亚组(N=2455;27%)中,ARPI+ADT较单用ADT显著改善OS(HR 0.65;95%CI 0.52-0.80),ARPI+D+ADT与ARPI+ADT无显著差异(HR 1.08;95%CI 0.65-1.79)
  • 异时高瘤负荷亚组(N=589;6.5%)中,ARPI+D+ADT较ARPI+ADT(HR 0.89;95%CI 0.43-1.85)及D+ADT(HR 0.90;95%CI 0.60-1.36)均无显著改善,ARPI+ADT与D+ADT无显著差异(HR 1.02;95%CI 0.45-2.28)
  • 异时低瘤负荷亚组(N=775;8.5%)中,ARPI+ADT较单用ADT显著改善OS(HR 0.43;95%CI 0.29-0.64),较D+ADT亦显著改善(HR 0.41;95%CI 0.24-0.70),ARPI+D+ADT与ARPI+ADT无显著差异(HR 1.56;95%CI 0.40-6.25)

临床怎么用

  • 同步高瘤负荷且适合多西他赛的患者推荐ARPI+多西他赛+ADT三联治疗
  • 同步低瘤负荷、异时高瘤负荷及异时低瘤负荷患者推荐ARPI+ADT双联治疗
  • 可获得ARPI且能耐受者不推荐多西他赛双联治疗

局限性

  • 无法校正所有相关变量,如影响医生决定是否给予多西他赛的患者及肿瘤相关因素

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: We aimed to assess the comparative effectiveness of contemporary systemic treatment options across patients with metastatic hormone-sensitive prostate cancer (mHSPC) across clinically relevant prognostic subgroups (synchronous high [SHV] and low [SLV] volume, and metachronous high [MHV] and low [MLV] volume). METHODS: This living network meta-analysis was conducted using the living interactive evidence (LIvE) synthesis framework. Phase 3 randomized controlled trials assessing treatment intensification with androgen receptor pathway inhibitors (ARPIs), docetaxel (D), or both were included. Mixed treatment comparisons were conducted for overall population and for each prognostic subgroup (SHV, SLV, MHV, and MLV). Overall survival (OS) and progression-free survival were assessed. KEY FINDINGS AND LIMITATIONS: The current report of a living systematic review includes a total of 11 trials (12 668 patients and 12 unique treatments). In the overall population, the results were consistent with those of a previous report. An analysis of OS by prespecified subgroups included nine clinical trials (8990 patients and eight unique treatments). In the SHV subgroup (N = 5171; 57%), ARPI + D + androgen deprivation therapy (ADT) led to a statistically significant improvement in OS compared with D + ADT (hazard ratio: 0.72; 95% confidence interval: 0.62-0.83) and ARPI + ADT (0.71; 0.53-0.97). In the SLV subgroup (N = 2455; 27%), ARPI + ADT led to a statistically significant improvement compared with ADT alone (0.65; 0.52-0.80). There was no statistically significant difference between ARPI + D + ADT and ARPI + ADT (1.08; 0.65-1.79). In the MHV subgroup (N = 589; 6.5%), no statistically significant improvement was observed with ARPI + D + ADT compared with ARPI + ADT (0.89; 0.43-1.85) and D + ADT (0.90; 0.60-1.36). There was no statistically significant difference between ARPI + ADT and D + ADT (1.02; 0.45-2.28). In the MLV subgroup (N = 775; 8.5%), ARPI + ADT led to a statistically significant improvement compared with ADT alone (0.43; 0.29-0.64) and D + ADT (0.41; 0.24-0.70). There was no statistically significant difference between ARPI + D + ADT and ARPI + ADT (1.56; 0.40-6.25). Inherent limitations of this analysis include the inability to account for all relevant variables such as the patient- and cancer-related factors that likely influenced the decision of physicians to offer docetaxel to patients. CONCLUSIONS AND CLINICAL IMPLICATIONS: Current evidence suggests that triplet systemic therapy is preferred for patients with SHV mHSPC who are fit for docetaxel. Androgen receptor pathway doublet therapy is preferred for all other patient subgroups compared with ADT alone. There is no role of docetaxel doublet in patients with access to ARPI therapy and if they are able to receive it.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Riaz IB, Ahmed Naqvi SA, Faisal KS, et al. Comparative Survival in Metastatic Hormone-sensitive Prostate Cancer by Volume of Disease and Timing of Metastasis: A Living Network Meta-analysis. Eur Urol. 2025. PMID: 41193370. doi:10.1016/j.eururo.2025.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。